Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyllis J Goodman

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
The Journal of Urology|January 10, 2004
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen, Phyllis J Goodman, John J Crowley, et al.
The Journal of Urology|April 24, 2024
Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention TrialCathee Till, Phyllis J Goodman, Catherine Tangen, et al.
The Journal of Urology|April 22, 2014
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?Yuanyuan Liang, Norma S Ketchum, Phyllis J Goodman, et al.
The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Controlled Clinical Trials|December 31, 2002
Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler, Kathryn B Gower, Phyllis J Goodman, et al.
Urology|September 24, 2013
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom scoreDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
The Journal of Urology|January 10, 2004
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen, Phyllis J Goodman, John J Crowley, et al.
The Journal of Urology|April 24, 2024
Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention TrialCathee Till, Phyllis J Goodman, Catherine Tangen, et al.
The Journal of Urology|April 22, 2014
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?Yuanyuan Liang, Norma S Ketchum, Phyllis J Goodman, et al.
The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Controlled Clinical Trials|December 31, 2002
Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler, Kathryn B Gower, Phyllis J Goodman, et al.
Urology|September 24, 2013
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom scoreDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 16